• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


One Ms really?

































There will not be a complete decapitation of the sales force for both K and S1P. NVS expects 1.7B for K in 2023–that takes boots on the ground. There will be realignments coming, but it will be less reduction than people are thinking.
 




They are calling it an “optimization” or “right-sizing” exercise. Hearing mirror territories with 2 reps for most, some smaller territories will just have 1 rep with maybe a virtual rep overlap. There will be territory realignments but very few drastic shifts. A few low volume “non viable” territories will be realigned so yeah if you have low to no volume I’d dust off your resume. Happening in early 2022. Both mirror reps will carry both products with Kesimpta being more heavily weighted product. Laverne and Victor are convinced sales will go up if we do this. They are basically ignoring Covid from here on out and expect you to do the same.
It’s the “be glad you have a job” sales approach…and we don’t care what you think
 
































Yes, to get your trimester bonus for may-aug will be nov. if you stick around through the end of the year you still get your sept-dec bonus. However, the true-up/v&b isn’t paid out until march so that 20% you would forfeit.